BioNTech SE

BNTX

Equity

ISIN null / Valor 50030055

NASDAQ (2026-03-31)

USD 88.88+4.26%

BioNTech SE
UMushroom community rating:

3.27 5 votes No rating yet

NegativeNeutralPositive

About company

BioNTech SE is a biotechnology company focused on improving global health through the research and development of immunotherapies. Founded by scientists and physicians, the company is dedicated to translating scientific advancements into life-saving treatments by leveraging a diverse toolbox of drug classes and platform technologies, including mRNA-based therapies, cell therapies, small molecules, antibodies, and other protein-based therapies. BioNTech's innovative approach aims to provide personalized and effective treatments for patients worldwide, with a particular focus on developing novel cell therapies for targeting cancer-specific antigens, such as chimeric antigen receptor (CAR) T cell therapies and T cell receptor (TCR) programs. Additionally, the company is exploring the combination of mRNA FixVac platform with CAR T product candidates to enhance the persistence of CAR-T cells in vivo.

Summarized from source with an LLMView SourceSector: Technology

Latest Results ():

Summarized from source with an LLMView Source

Key figures

-2.39%1Y

-28.7%3Y

-18.6%5Y

Performance

47.5%1Y

42.7%3Y

57.0%5Y

Volatility

22338 M

Market cap (USD)

857,129

Daily traded volume (Shares)

114.24 / 110.81

1 day high/low (USD)

0.00 / 0.00

52 weeks high/low (USD)

01 January, 2022

Dividend ex-date

0.00

Dividend (USD)

0.00%

Dividend yield (p.a.)

0.002022

0.002023

0.002024

Est dividend (USD)

0.00%2022

0.00%2023

0.00%2024

Est dividend yield

10.00

P/E ratio

00.002022

00.002023

00.002024

Est P/E ratio

0.00

EPS (USD)

0.002022

0.002023

0.002024

Est EPS (USD)

Ratings & reviews

3.27

5 votes

Performance:

3.00

Innovation:

3.33

Society:

3.40

Nature:

2.67

mauro massaini

Switzerland, 18 Mar 2026

grate

Tommy Ebneter

Switzerland, 14 Apr 2025

Spannende, zukunftsorientierte Aktie mit hohem Potenzial – aber auch erhöhtem Risiko. Besonders interessant für langfristige und forschungsaffine Anleger.